BioCentury | Jan 11, 2019
Clinical News

Plinabulin meets in Phase III for chemotherapy-induced neutropenia

...NASDAQ:AMGN). BeyondSpring Inc. (NASDAQ:BYSI), New York, N.Y. Product: Plinabulin (BPI-2358) Business: Hematology Molecular target: Tubulin; Guanine nucleotide exchange factor H1...
...the first cycle of chemotherapy Status: Interim Phase III data Milestone: N/A Hongjiang Li plinabulin (BPI-2358, NPI-2358) BeyondSpring Inc. Guanine nucleotide exchange factor H1...
BioCentury | Mar 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: February 2018

...AbbVie Inc. (NYSE:ABBV) Product Profile Cancer; hematology Brain cancer; neutropenia; non-small cell lung cancer (NSCLC) Guanine nucleotide exchange factor H1...
BioCentury | Feb 16, 2018
Clinical News

BeyondSpring reports Phase II data for plinabulin to prevent chemotherapy-induced neutropenia

...of hospitalizations and documented infections. Plinabulin is a halimide-derived tumor vascular disrupting agent (VDA) and guanine nucleotide exchange factor H1...
...NASDAQ:AMGN). BeyondSpring Inc. (NASDAQ:BYSI), New York, N.Y. Product: Plinabulin (BPI-2358) Business: Hematology Molecular target: Tubulin; Guanine nucleotide exchange factor H1...
...II data (1H18); interim Phase III data (2H18) Jaime De Leon BPI-2358 Neulasta plinabulin American Society of Clinical Oncology Amgen Inc. BeyondSpring Inc. Guanine nucleotide exchange factor H1...
Items per page:
1 - 3 of 3